Navigation Links
BAETA Corp Initiates Clinical Trial at NYU School of Medicine to Measure Efficacy of Pain Recording Device
Date:5/16/2011

FORT LEE, N.J., May 16, 2011 /PRNewswire/ -- BAETA Corp. (OTCBB: BAEA) announced today that the NYU School of Medicine will conduct a clinical trial to measure the efficacy of the Company's "MyHealthTrends for Pain" handheld device during intra-operative, pre- and post-surgical periods. This trial will compare the current standard of pain care monitoring to Baeta's device which facilitates accurate data collection.

Michael Haile, MD, director of Clinical Research at NYU School of Medicine will oversee the initiative as the Principal Investigator.  "We are interested in the practical application of a portable, handheld device for patients to quantify pain and the ability to translate this information into enhanced treatment regimens and outcomes relative to the current standard of pain care monitoring," said Dr. Haile.

The protocol has been reviewed and approved by NYU School of Medicine's Institutional Review Board (IRB).

"We look forward to the opportunity to determine if the standard of pain care monitoring can be advanced using this technology," said Dr. Alexander Gak, Chairman of Baeta Corp. "With limited tools to quantify pain, this is an important initiative for any individual suffering from acute or chronic pain," said Gak.  

Upon conclusion of the clinical trial Baeta intends to apply for a CPT reimbursement code. "This is an important step for Baeta Corp's commercialization of its advanced patient care products," stated Len Pushkantser, CEO of Baeta Corp. Physicians, hospitals, and other health care providers use CPT codes to report medical services to private and public health insurance systems for purposes of reimbursement. 

About Baeta Corp.

Baeta Corp. (OTC.BB: BAEA) is a technology-enabled health improvement company whose objective is to empower patients to elevate their role in the prevention, diagnosis, treatment, and recovery from illnesses. Baeta Corp. develops innovative, technology-driven healthcare information solutions enabling patients to easily capture health-related data. Please visit Baeta Corp. at http://www.baetacorp.com/ for more information about our products.

Not a Broker/Dealer or Financial Advisor

Baeta Corp. is not a Registered Broker/Dealer or a Financial Advisor, nor does it hold itself out to be a Registered Broker/Dealer or Financial Advisor. All material presented in this press release, on the Company's website or other media is not to be regarded as investment advice and is only for informative purposes. Readers should verify all claims and conduct their own due diligence before investing in Baeta Corp. Investing in small-cap, micro cap and penny stock securities is speculative and carries a high degree of risk.

No Offer of Securities

None of the information featured in this press release constitutes an offer or solicitation to purchase or to sell any securities of Baeta Corp.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS

Information presented in this press release contains "forward looking statements" within the meaning of Section 27A of the Securities Exchange Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements." Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects," "foresee," "expects," "will," "anticipates," "estimates," "believes," "understands," or that by statements indicating certain actions "may," "could," or "might" occur. Understand there is no guarantee past performance will be indicative of future results.

None of the information contained on the Baeta Corp. website is incorporated by reference herein.

For additional information, please contact:
Mr. Leonid Pushkantser
Chief Executive Officer
1 Bridge Plaza Suite 275
Fort Lee, NJ 07024
(201) 471-0988, Extension 106

Or

Jeffrey Staller
President
Heritage Corporate Services, Inc.
(888) 604- 7064
www.HeritageIR.com


'/>"/>
SOURCE BAETA Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BAETA Corp. Expands Market Awareness Programs
2. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
7. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
8. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. Prolexys Pharmaceuticals Initiates Phase 1 Study
11. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
Breaking Medicine Technology:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... its new partnership with the Home Care Association of America (HCAOA). This agreement ... Private Duty Accreditation services, as well as discounts on Accreditation University (AU) educational ...
(Date:4/28/2017)... ... , ... Beginning in 2017, Ridgecrest Herbals will be phasing out the homeopathic ... Extra Strength formula. To ensure that the effectiveness of Clear Lungs Extra Strength is ... , Removal of the homeopathic element , Adding their patented ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. ... GlycoMark test throughout the Northeast U.S. , GlycoMark is the only clinically ... GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic excursions, ...
(Date:4/28/2017)... Fairfax, VA (PRWEB) , ... April 28, 2017 , ... ... elected volunteer board members and officers for 2017-2018. The annual board election process has ... serving on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, ...
(Date:4/28/2017)... ... , ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical ... Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord ... donate. , “Women’s Hospital at Renaissance has been a collection partner for the ...
Breaking Medicine News(10 mins):